PASSAGE BIO INC. news, videos and press releases
For more news please use our advanced search feature.
PASSAGE BIO INC. - More news...
PASSAGE BIO INC. - More news...
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
- Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
- Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
- Passage Bio Welcomes Tom Kassberg to Board of Directors
- Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
- Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
- Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
- Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
- Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
- Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities
- Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
- Passage Bio Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology Conference
- Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Passage Bio to Present at Chardan’s 7th Annual Genetic Medicines Conference
- Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study
- Passage Bio to Participate in Upcoming Investor Conferences
- Passage Bio Welcomes Dolan Sondhi, Ph.D. to Board Of Directors
- Passage Bio to Present at Goldman Sachs 44th Annual Global Healthcare Conference
